Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer. (NEOLBC)

The aim of this prospective, randomized, multicenter, open-label, phase II study is to test if chemotherapy can be replaced by the combination of ribociclib plus letrozole as a neo-adjuvant therapy for patients with non-metastatic primary luminal breast cancer.

Study Overview

• Status: Active, not recruiting
• Conditions: Breast Neoplasms
• Intervention / Treatment: Drug: Letrozole; Drug: Chemotherapy; Drug: Ribociclib plus letrozole

Detailed Description

Based on Ki67 levels after two weeks of initial letrozole treatment in postmenopausal patients with hormone receptor positive, HER2 negative, stage II/III breast cancer, patients are either advised to continue letrozole treatment (if Ki67 <1%) or will be randomized between standard chemotherapy (AC-T) or ribociclib in combination with letrozole (if Ki67 ≥1%).

• Study Type: Interventional
• Enrollment (Estimated): 100
• Phase: Phase 2

Contacts and Locations

Study Locations

• Netherlands
  • 's-Hertogenbosch, Netherlands
    • Jeroen Bosch Ziekenhuis
  • Almelo, Netherlands
    • Ziekenhuisgroep Twente
  • Amstelveen, Netherlands
    • Ziekenhuis Amstelland
  • Amsterdam, Netherlands
    • Onze Lieve Vrouwe Gasthuis
  • Amsterdam, Netherlands
    • Nederlands Kanker Instituut - Antoni van Leeuwenhoek
  • Apeldoorn, Netherlands
    • Gelre Ziekenhuizen
  • Breda, Netherlands
    • Amphia ziekenhuis
  • Delft, Netherlands
    • Stichting Reinier Haga Groep (Reinier de Graaf Gasthuis)
  • Den Haag, Netherlands
    • Haaglanden Medisch Centrum
  • Den Haag, Netherlands
    • Haga ziekenhuis
  • Deventer, Netherlands
    • Stichting Deventer Ziekenhuisgroep
  • Eindhoven, Netherlands
    • Catharina Ziekenhuis
  • Eindhoven, Netherlands
    • Máxima Medisch Centrum
  • Gouda, Netherlands
    • Groene Hart Ziekenhuis
  • Haarlem, Netherlands
    • Spaarne Gasthuis
  • Harderwijk, Netherlands
    • Ziekenhuis St. Jansdal
  • Hilversum, Netherlands
    • Tergooi ziekenhuizen
  • Hoorn, Netherlands
    • Westfriesgasthuis
  • Leiden, Netherlands
    • Leiden University Medical Center
  • Maastricht, Netherlands
    • Academisch Ziekenhuis Maastricht
  • Nijmegen, Netherlands
    • Canisius-Wilhelmina Ziekenhuis
  • Roermond, Netherlands
    • Laurentius Ziekenhuis
  • Roosendaal, Netherlands
    • Bravis Ziekenhuis
  • Sneek, Netherlands
    • Antonius Ziekenhuis
  • Tiel, Netherlands
    • Ziekenhuis Rivierenland
  • Tilburg, Netherlands
    • Elisabeth TweeSteden Ziekenhuis
  • Venlo, Netherlands
    • VieCuri Medisch Centrum
  • Winterswijk, Netherlands
    • Streekziekenhuis Koningin Beatrix
  • Zwolle, Netherlands
    • Isala

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Postmenopausal women presenting with histological proven (core biopsy material) hormone receptor positive (ER≥50%, PR any), HER2 negative, stage II/ III breast cancer.
• Measurable disease (breast and/or lymph nodes)
• WHO 0-2
• Adequate bone marrow function (within 4 weeks prior to registration): WBC≥3.0x109/l, neutrophils ≥1.5 x 109/l, platelets ≥100 x 109/l
• Adequate liver function (within 4 weeks prior to registration): bilirubin ≤1.5 x upper limit of normal (UNL) range, ALAT and/or ASAT ≤2.5 x UNL, Alkaline Phosphatase ≤5 x UNL
• Adequate renal function (within 4 weeks prior to registration): the calculated creatinine clearance should be ≥50 ml/min
• Accessible for treatment and follow-up
• Written informed consent

Inclusion criteria randomization specific:

In order to be eligible to be randomized in this study, a subject must meet all of the following criteria:

• Registration in the NEOLBC trial before 2 weeks biopsy
• Use of letrozole
• Outcome central Ki67 determination in two weeks biopsy available.

Exclusion Criteria:

• Evidence of distant metastases (M1)
• Previous invasive breast cancer
• Prior chemotherapy, radiation therapy or hormonal therapy with the exception of patients who received letrozole ≤ 14 days (+ max. 4 days) prior to registration and who are still on letrozole.
• Previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix.
• Peripheral neuropathy > grade 2, whatever the cause
• Serious other diseases as infections (hepatitis B, C and HIV), recent myocardial infarction, clinical signs of cardiac failure or clinically significant arrhythmias or on screening, any of the following cardiac parameters: bradycardia (heart rate <50 at rest) or QTcF ≥450 msec.
• Known hypersensitivity reaction to any of the components of the treatment (peanuts, soy)
• Currently receiving warfarin or other coumarin derived anti-coagulant, for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowed.

• Currently receiving any of the following substances and cannot be discontinued 7 days prior to randomisation:

  • Known strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit hybrids, pummelo's, star-fruit, pomegranate and Seville oranges.
  • That have a known risk to prolong the QT interval or induce Torsades de Pointes.
  • That have a narrow therapeutic window and are predominantly metabolized through CYP3A4/5.
  • Herbal preparations/medications, dietary supplements.
• Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Advise letrozole, treatment choice free.; All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of <1% in the biopsy taken after those two weeks of treatment are advised to stay on letrozole treatment until surgery. However, treatment choice is free.	Drug: Letrozole; Letrozole 2.5 mg daily.
Active Comparator: Chemotherapy; All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of ≥1% in the biopsy taken after those two weeks of treatment are randomized between chemotherapy (standard AC-T chemotherapy) or ribociclib plus letrozole (ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks)).	Drug: Chemotherapy; Dose dense AC-T chemotherapy: consisting of 4 cycles of AC (doxorubicin and cyclophosphamide at a dose of 60 and 600 mg/m² as an i.v. bolus, respectively) 2-weekly, plus G-CSF (6 mg once per cycle) 24-48 hr after chemotherapy, followed by cycles of T (4 cycles docetaxel 100 mg/m² 3-weekly or 12 cycles paclitaxel 80 mg/m2 weekly).
Experimental: Ribociclib plus letrozole; All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of ≥1% in the biopsy taken after those two weeks of treatment are randomized between chemotherapy (standard AC-T chemotherapy) or ribociclib plus letrozole (ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks)).	Drug: Ribociclib plus letrozole; Ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference in complete cell cycle arrest (CCCA; defined as Ki67 IHC <1%) between ribociclib plus letrozole and chemotherapy in the surgical specimen.	Determine if ribociclib plus letrozole gives a ≥100% improvement in CCCA as compared to chemotherapy in the surgical specimen.	CCCA will be determined in the surgical specimen, which is around 7 months after start of initial letrozole treatment.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Correlation between Ki67 IHC scored manually, IHC scored automatically (Vectra ® 3) and Ki67 mRNA.	The correlation between the different Ki67 measurements will be determined in the primary core biopsy, two weeks biopsy and surgical specimen.	Ki67 measurements will be done in the primary core biopsy (baseline), two weeks biopsy (done after two weeks of initial letrozole treatment) and the surgical specimen (which is around 7 months after start of initial letrozole treatment).
Correlation between ER pathway activity at baseline, after two weeks letrozole and at surgery and clinical outcome.	The ER pathway activity will be determined in the primary core biopsy, two weeks biopsy and surgical specimen and then correlated with clinical outcome. Activity will be determined using a Bayesian network model of the ER transcriptional program, which interprets the pathway target genes' mRNA levels (from Affymetrix HG-U133Plus2.0 arrays) and infers a probability that the ER pathway is active in a certain sample.	ER pathway activity will measured in the primary core biopsy (baseline), two weeks biopsy (done after two weeks of initial letrozole treatment) and the surgical specimen (which is around 7 months after start of initial letrozole treatment).
Difference in pathologic response (pCR and response according to Miller and Payne) between the randomized study arms.	The pathologic response will be determined in the surgical specimen of the patients in the randomized study arms where after the difference between the two groups can be determined.	pCR and response according to Miller and Payne will be determined in the surgical specimen, which is around 7 months after start of initial letrozole treatment.
Change in tumor biology and biomarkers (ER, PR, HER2, Rb, Ki67) at baseline, after 2 weeks letrozole and at surgery.	Tumor biology and biomarkers will be determined in the primary core biopsy, two weeks biopsy and surgical specimen, where after the change in tumor biology and biomarkers over time can be determined.	Tumor biology and biomarkers will be assessed in the primary core biopsy (baseline), two weeks biopsy (done after two weeks of initial letrozole treatment) and the surgical specimen (which is around 7 months after start of initial letrozole treatment).
Toxicity according to NCI CTCAE v4.03 all grades and grade III/IV.	Toxicities are graded according to NCI CTCAE v4.03.	Toxicity will be assessed from start treatment up to 30 days following the last dose of treatment.
Correlation of tumor measurements between standard MRI (using RECIST 1.1) and palpation (largest diameter in cm) at baseline, after AC/before T or 8 weeks of definitive neoadjuvant therapy and pre-surgery.	The correlation of tumor measurements between MRI and palpation will be determined at three different time points.	Tumor measurements (MRI and palpation) will be performed at baseline, after AC/before T or 8 weeks of definitive neoadjuvant therapy and pre-surgery (which is around 7 months after start of initial letrozole treatment).
Descriptive analysis of event free survival (EFS) at 3 and 5 years.	EFS is defined as the time from randomization to the first date of local, regional, or distant relapse, second primary invasive breast cancer including contralateral breast cancer, progression according to RECIST 1.1 or death due to any cause which ever occurred first.	EFS will be determined after 3 and 5 years.
Descriptive analysis of overall survival (OS) at 3 and 5 years.	OS is defined as the time from randomization to date of death.	Time Frame: OS will be determined after 3 and 5 years.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in ERα DNA binding signatures (Chip-seq) between baseline and after 2 weeks letrozole.	ERα DNA binding will be determined in the primary core biopsy and two weeks biopsy, where after the change in these measurements over time can be determined.	ERα DNA binding signatures will be assessed in the primary core biopsy (baseline) and the two weeks biopsy (done after two weeks of initial letrozole treatment).
Change in gene expression profiles (RNA-seq) between baseline and after 2 weeks letrozole.	Gene expression profiling will be determined in the primary core biopsy and two weeks biopsy, where after the change in these measurements over time can be determined.	Gene expression profiles will be assessed in the primary core biopsy (baseline) and the two weeks biopsy (done after two weeks of initial letrozole treatment).

Collaborators and Investigators

• Sponsor: Borstkanker Onderzoek Groep
• Collaborators: Novartis; Philips Healthcare
• Investigators: Principal Investigator: Judith R Kroep, MD PhD, Leiden University Medical Center; Principal Investigator: Sabine C Linn, Prof. MD, NKI-AVL; Principal Investigator: Gerrit-Jan Liefers, MD PhD, Leiden University Medical Center; Study Director: A. E van Leeuwen-Stok, PhD, BOOG Study Center

Publications and helpful links

Helpful Links

• Information NEOLBC study on BOOG website (sponsor).

Study record dates

Study Major Dates

• Study Start (Actual): June 15, 2019
• Primary Completion (Estimated): March 4, 2026
• Study Completion (Estimated): August 1, 2027

Study Registration Dates

• First Submitted: August 28, 2017
• First Submitted That Met QC Criteria: September 12, 2017
• First Posted (Actual): September 14, 2017

Study Record Updates

• Last Update Posted (Actual): August 18, 2023
• Last Update Submitted That Met QC Criteria: August 16, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Keywords: Breast cancer; Chemotherapy; Ribociclib; Letrozole; CDK4; CDK6; Ki67; NEOLBC
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Hormone Antagonists; Aromatase Inhibitors; Steroid Synthesis Inhibitors; Estrogen Antagonists; Letrozole
• Other Study ID Numbers: BOOG-2017-01; 2017-000676-29 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No